Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues

Glycobiology

Volumn 21, Issue 5, 2011, Pages 584-594

  Souady, Jamal ^a,e   Hülsewig, Marcel ^b,e   Distler, Ute ^b,e   Haier, Jörg ^c   Denz, Axel ^d   Pilarsky, Christian ^d   Senninger, Norbert ^c   Dreisewerd, Klaus ^a   Peter Katalinić, Jasna ^a   Müthing, Johannes ^b  

^a Institute of Medical Physics and Biophysics   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

IR MALDI o TOF MS; sialyltransferases; targeted therapies; TLC immunostain; tumor associated gangliosides

Indexed keywords

BETA GALACTOSIDE ALPHA 2,6 SIALYLTRANSFERASE 1; BETA GALACTOSIDE BETA 2,3 SIALYLTRANSFERASE 6; GANGLIOSIDE; GANGLIOSIDE CD75S; GANGLIOSIDE ISO CD75S; LIPID; MESSENGER RNA; SIALYLTRANSFERASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNODETECTION; LIVER; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; THIN LAYER CHROMATOGRAPHY; TIME OF FLIGHT MASS SPECTROMETRY; TUMOR DIFFERENTIATION;

ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; COHORT STUDIES; GANGLIOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MOLECULAR STRUCTURE; SIALYLTRANSFERASES; TRANSCRIPTION, GENETIC; TUMOR BURDEN;

EID: 79953898237     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq200     Document Type: Article

References (80)

1. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H. 2008. Phase I trial of rViscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer. 44:1657-1662.
2. Campanero-Rhodes MA, Smith A, Chai W, Sonnino S, Mauri L, Childs RA, Zhang Y, Ewers H, Helenius A, Imberty A, et al. 2007. N-Glycolyl GM1 ganglioside as a receptor for simian virus 40. J Virol. 81:12846-12858. (Pubitemid 350156922)
3. Cao Y, Karsten U, Otto G, Bannasch P. 1999. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and α2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch. 434:503-509. (Pubitemid 29281307)
4. Cao Y, Merling A, Crocker PR, Keller R, Schwartz-Albiez R. 2002. Differential expression of β-galactoside α2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab Invest. 82:1515-1524. (Pubitemid 35332910)
5. Chester MA. 1999. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids. Recommendations 1997. Glycoconj J. 16:1-6.
6. Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, Campanero-Rhodes MA, Zhang Y, Eickmann M, Kiso M, et al. 2009. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 27:797-799.
7. Chu KU, Ravindranath MH, Gonzales A, Nishimoto K, Tam WY, Soh D, Bilchik A, Katopodis N, Morton DL. 2000. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer. 88:1828-1836. (Pubitemid 30212992)
8. Crispe IN. 2009. The liver as a lymphoid organ. Annu Rev Immunol. 27:147-163.
9. Dall'Olio F, Chiricolo M. 2001. Sialyltransferases in cancer. Glycoconj J. 18:841-850. (Pubitemid 36315048)
10. Dall'Olio F, Chiricolo M, D'Errico A, Gruppioni E, Altimari A, Fiorentino M, Grigioni WF 2004. Expression of (3-galactoside oc2,6 sialyltransferase and oc2,6-sialylated glycoconjugates in normal human liver, hepatocarci- noma, and cirrhosis. Glycobiology. 14:39-49. (Pubitemid 38159407)
11. Deng W, Li R, Guerrera M, Liu Y, Ladisch S. 2002. Transfection of glucosyl- ceramide synthase antisense inhibits mouse melanoma formation. Glycobiology. 12:145-152. (Pubitemid 34567860)
12. Distler U, Hülsewig M, Souady J, Dreisewerd K, Haier J, Senninger N, Friedrich AW, Karch H, Hillenkamp F, Berkenkamp S, et al. 2008. Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated gly- cosphingolipids in hepatocellular and pancreatic cancer. Anal Chem. 80:1835-1846. (Pubitemid 351458025)
13. Distler U, Souady J, Hülsewig M, Drmi-Hofman I, Haier J, Denz A, Grützmann R, Pilarsky C, Senninger N, Dreisewerd K, et al. 2008. Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Mol Cancer Ther. 7:2464-2475.
14. Distler U, Souady J, Hülsewig M, Drmi-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, et al. 2009. Shiga toxin receptor Gb3Cer/CD77: Tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE. 4:e6813.
15. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. 2006. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res. 66:5901-5909. (Pubitemid 43927145)
16. Feizi T. 1985. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 314:53-57. (Pubitemid 15142022)
17. Feizi T. 2000. Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev. 173:79-88. (Pubitemid 30095212)
18. Fredman P, Hedberg K, Brezicka T. 2003. Gangliosides as therapeutic targets for cancer. BioDrugs. 17:155-167. (Pubitemid 36693681)
19. Hakomori S. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:5309-5318. (Pubitemid 27011703)
20. Hakomori S, Patterson CM, Nudelman E, Sekiguchi K. 1983. A monoclonal antibody directed to N-acetylneuraminosyl-oc2 -? 6-galactosyl residue in gangliosides and glycoproteins. J Biol Chem. 258:11819-11822.
21. Hamilton SR, Aaltonen LA. 2000. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press.
22. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. 2001. The human sialytransferase family. Biochimie. 83:727-737.
23. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. 2007. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8: R19.
24. Igarashi Y, Kannagi R. 2010. Glycosphingolipids as mediators of phenotypic changes associated with development and cancer progression. J Biochem. 147:3-8.
25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin. 59:225-249.
26. Johannes L, Römer W. 2010. Shiga toxins-From cell biology to biomedical applications. Nat Rev Microbiol. 8:105-116.
27. Kannagi R. 2000. Monoclonal anti-glycosphingolipid antibodies. Methods Enzymol. 312:160-179.
28. Kannagi R, Sakuma K, Miyazaki K, Lim K-T, Yusa A, Yin J, Izawa M. 2010. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. Cancer Sci. 101:586-593.
29. Karlsson KA. 2000. The human gastric colonizer Helicobacter pylori: A challenge for host-parasite glycobiology. Glycobiology. 10:761-771.
30. Kaucic K, Liu Y, Ladisch S. 2006. Modulation of growth factor signaling by gangliosides: Positive or negative? Methods Enzymol. 417:168-185. (Pubitemid 44792709)
31. Kitagawa H, Paulson JC. 1994. Cloning of a novel α2,3- sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups. J Biol Chem. 269:1394-1401.
32. Kniep B, Schäkel K, Nimtz M, Schwartz-Albiez R, Schmitz M, Northoff H, Vilella R, Gramatzki M, Rieber EP. 1999. Differential expression of α2-6 sialylated polylactosamine structures by human B and T cells. Glycobiology. 9:399-406. (Pubitemid 29182156)
33. Kono M, Ohyama Y, Lee YC, Hamamoto T, Kojima N, Tsuji S. 1997. Mouse β-galactoside α2,3-sialyltransferases: Comparison of in vitro substrate specificities and tissue specific expression. Glycobiology. 7:469-479. (Pubitemid 27246720)
34. Krzewinski-Recchi MA, Julien S, Juliant S, Teintenier-Lelièvre M, Samyn-Petit B, Montiel MD, Mir AM, Cerutti M, Harduin-Lepers A, Delannoy P. 2003. Identification and functional expression of a second human β-galactoside α2,6-sialyltransferase, ST6Gal II. Eur J Biochem. 270:950-961. (Pubitemid 36315338)
35. Lehoux S, Groux-Degroote S, Cazet A, Dhaenens CM, Maurage CA, Caillet-Boudin ML, Delannoy P, Krzewinski-Recchi MA. 2010. Transcriptional regulation of the human ST6GAL2 gene in cerebral cortex and neuronal cells. Glycoconj J. 27:99-114.
36. Levery SB. 2005. Glycosphingolipid structural analysis and glycosphingolipi-domics. Methods Enzymol. 405:300-369.
37. Li Y, Teneberg S, Thapa P, Bendelac A, Levery SB, Zhou D. 2008. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology. 18:158-165. (Pubitemid 351168254)
38. Li Y, Zhou D, Xia C, Wang PG, Levery SB. 2008. Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry. Glycobiology. 18:166-176. (Pubitemid 351168255)
39. Liu Y, Yan S, Wondimu A, Bob D, Weiss M, Sliwinski K, Villar J, Notario V, Sutherland M, Colberg-Poley AM, et al. 2010. Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene. 29:3297-3306.
40. Lopez PHH, Schnaar RL. 2009. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol. 19:549-567.
41. Månsson JE, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L. 1985. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta. 834:110-117. (Pubitemid 15097628)
42. Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, de Haas M, Goyert S, Hadam M, Hart D, et al. 2002. CD antigens 2002. Blood. 99:3877-3880.
43. Meisen I, Peter-Katalini J, Müthing J. 2003. Discrimination of neolacto-series gangliosides with α2-3- and α2-6-linked N-acetylneuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quadrupole TOF MS. Anal Chem. 75:5719-5725. (Pubitemid 37356452)
44. Miller-Podraza H, Johansson L, Johansson P, Larsson T, Matrosovich M, Karlsson KA. 2000. A strain of human influenza A virus binds to extended but not short gangliosides as assayed by thin-layer chromatography overlay. Glycobiology. 10:975-982.
45. Müsken A, Souady J, Dreisewerd K, Zhang W, Distler U, Peter-Katalini? J, Miller-Podraza H, Karch H, Müthing J. 2010. Application of thin-layer chromatography/infrared matrix-assisted laser desorption/ ionization orthogonal time-of-flight mass spectrometry to structural analysis of bacteria-binding glycosphingolipids selected by affinity detection. Rapid Commun Mass Spectrom. 24:1032-1038.
46. Müthing J. 1998. TLC in structure and recognition studies of glycosphingoli-pids. In: EF Hounsell, editor. Methods in Molecular Biology, Vol. 76: Glycoanalysis Protocols. Totawa (NJ): Humana Press. p. 183-195.
47. Müthing J, Burg M, Möckel B, Langer M, Metelmann-Strupat W, Werner A, Neumann U, Peter-Katalini? J, Eck J. 2002. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated neolacto-series gangliosides. Glycobiology. 12:485-497.
48. Müthing J, Distler U. 2010. Advances on the compositional analysis of glyco-sphingolipids combining thin-layer chromatography with mass spec-trometry. Mass Spectrom Rev. 29:425-479.
49. Müthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H, Neumann U, Peter-Katalini? J. 2004. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Acα2-6Galβ1-4GlcNAc residues. Biochemistry. 43:2996-3007. (Pubitemid 38352250)
50. Müthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U, Langer M, Witthohn K, Milosevi? J, Peter-Katalini? J. 2005. Tumor-associated CD75s-gangliosides and CD75s-bearing glycoproteins with Neu5Acα2- 6Galβ1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J. 19:103-105. (Pubitemid 40069932)
51. Müthing J, Schweppe CH, Karch H, Friedrich AW. 2009. Shiga toxins, glyco-sphingolipid diversity, and endothelial cell injury. Thromb Haemost. 101:252-264.
52. Nemeth E, Baird AW, O'Farrelly C. 2009. Microanatomy of the liver immune system. Semin. Immunopathol. 31:333-343.
53. Nimrichter L, Burdick MM, Aoki K, Laroy W, Fierro MA, Hudson SA, von Seggern CE, Cotter RJ, Bochner BS, Tiemeyer M, et al. 2008. E-selectin receptors on human leukocytes. Blood. 112:3744-3752.
54. Okada Y, Arima T, Nagashima H, Fukushi Y, Kannagi R, Kaizu T. 1986. Human hepatocellular carcinoma-associated changes of glycosphingolipids detected by two monoclonal antibodies FH2 and IB9. J Hepatol. 2:430-440. (Pubitemid 16086606)
55. Okajima T, Fukumoto S, Miyazaki H, Ishida H, Kiso M, Furukawa K, Urano T, Furukawa K. 1999. Molecular cloning of a novel α2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J Biol Chem. 274:11479-11486.
56. Pang RW, Poon RT. 2007. From molecular biology to targeted therapies for hepatocellular carcinoma: The future is now. Oncology. 72:30-44. (Pubitemid 350256663)
57. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Pérez R. 2008. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther. 7:2033-2041.
58. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 132:365-386.
59. Sasaki K, Watanabe E, Kawashima K, Sekine S, Dohi T, Oshima M, Hanai N, Nishi T, Hasegawa M. 1993. Expression cloning of a novel Galβ(1-3/ 1-4) GlcNAcα2,3-sialyltransferase using lectin resistance selection. J Biol Chem. 268:22782-22787. (Pubitemid 23318339)
60. Schnaar RL. 1991. Glycosphingolipids in cell surface recognition. Glycobiology. 1:477-485.
61. Schöffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H. 2005. Weekly 24 h infusion of aviscu-mine (rViscumin): A phase I study in patients with solid tumours. Eur J Cancer. 41:1431-1438. (Pubitemid 40826467)
62. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, et al. 2004. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: A study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol. 15:1816-1824. (Pubitemid 40017162)
63. Sharon N. 2007. Lectins: Carbohydrate-specific reagents and biological recognition molecules. J Biol Chem. 282:2753-2764.
64. Sharon N. 2008. Lectins: Past, present and future. Biochem Soc Trans. 36:1457-1460.
65. Sobin L, Wittekind C. 2002. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss.
66. Sonnino S, Mauri L, Chigorno V, Prinetti A. 2006. Gangliosides as components of lipid membrane domains. Glycobiology. 17:1R-13R.
67. Souady J, Soltwisch J, Dreisewerd K, Haier J, Peter-Katalini J, Müthing J. 2009. Structural profiling of individual glycosphingolipids in a single thin-layer chromatogram by multiple sequential immunodetection matched with direct IR-MALDI-o-TOF mass spectrometry. Anal Chem. 81:9481-9492.
68. Stults CL, Sweeley CC, Macher BA. 1989. Glycosphingolipids: Structure, biological source, and properties. Methods Enzymol. 179:167-214. (Pubitemid 20044395)
69. Suzuki Y, Nishi H, Hidari K, Hirabayashi Y, Matsumoto M, Kobayashi T, Watarai S, Yasuda T, Nakayama J, Maeda H. 1991. A new monoclonal antibody directed to sialylα2-3lactoneotetraosylceramide and its application for detection of human gastrointestinal neoplasms. J Biochem. 109:354-360.
70. Taieb J, Barbare JC, Rougier P. 2006. Medical treatments for hepatocellular carcinoma (HCC): What's next? Ann Oncol. 17:x308-x314. (Pubitemid 44542028)
71. Takashima S, Tsuji S, Tsujimoto M. 2002. Characterization of the second type of human β-galactoside α2,6-sialyltransferase (ST6Gal II), which sia-lylates Galβ1,4GlcNAc structures on oligosaccharides preferentially: Genomic analysis of human sialyltransferase genes. J Biol Chem. 277:45719-45728. (Pubitemid 35417547)
72. Taki T, Rokukawa C, Kasama T, Handa S. 1992. Human hepatoma ganglio-sides: Occurrence of a novel I-type glycolipid with NeuAcα2-6Gal structure. Cancer Res. 52:4805-4811.
73. Taki T, Yamamoto K, Takamatsu M, Ishii K, Myoga A, Sekiguchi K, Ikeda I, Kurata K, Nakayama J, Handa S. 1990. Accumulation of gangliosides with N-acetylneuraminosyl(α2-6)lactosamine structure in primary human hepa-toma. Cancer Res. 50:1284-1290. (Pubitemid 20084024)
74. Tanno M, Yamada H, Kyomasu Y, Inaniwa Y, Hano H, Myoga A. 1993. Immunohistochemical localization of ganglioside components in hepatocel-lular carcinoma and liver cirrhosis using monoclonal antibody. Lab Invest. 68:456-464. (Pubitemid 23136166)
75. Tsuji S. 1996. Molecular cloning and functional analysis of sialyltransferases. J Biochem. 120:1-13. (Pubitemid 26258239)
76. Weiss M, Hettmer S, Smith P, Ladisch S. 2003. Inhibition of melanoma tumor growth by novel inhibitor of glucosylceramide synthase. Cancer Res. 63:3654-3658. (Pubitemid 36793049)
77. Yin J, Hashimoto A, Itawa M, Miyazaki K, Chen G-Y, Takematsu H, Kozutsumi Y, Suzuki A, Furuhata K, Cheng F-L, et al. 2006. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 66:2937-2945.
78. Yin J, Miyazaki K, Shaner RL, Merrill AH, Jr, Kannagi R. 2010. Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glyco-lipid tumor markers. FEBS Lett. 584:1872-1878.
79. Zhu AX. 2008. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 112:250-259.
80. + suppressor T cells. Int Immunol. 15:1389-1399. (Pubitemid 37369332)